Condition: Unresectable Pancreatic Cancer · Unresectable Bile Duct Carcinoma · Unresectable Biliary Tract Carcinoma · Sponsor: National Cancer Center, Korea
* Clinical trial phase: Phase 2 * Intervention model: Control group * Group allocation: Randomized controlled trial * Research perspective: Prospective study * Participating centers: Multicenter study * Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first. * The intervention period is from the date of IRB approval to December 31st, 2025 * The follow-up duration is one year, and the statistical analysis duration is six months * The total research period is from the date of IRB approval to June 30th, 2026
This description comes directly from the study's public registry record.
Sangmyung Woo, M.D · 82-31-920-1733 · wsm@ncc.re.kr
Jung Won Chun, M.D · 82-31-920-0887 · deli4928@ncc.re.kr
Always discuss trial participation with your own doctor first.
| NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu, | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06135896